Onabotulinumtoxina Intradetrusorial Injections and NGF Expression (Onab/A-NGF)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01629433 |
Recruitment Status
:
Completed
First Posted
: June 27, 2012
Last Update Posted
: June 27, 2012
|
Sponsor:
University Of Perugia
Collaborator:
Allergan
Information provided by (Responsible Party):
Antonella Giannantoni, University Of Perugia
Tracking Information | |||
---|---|---|---|
First Submitted Date | June 20, 2012 | ||
First Posted Date | June 27, 2012 | ||
Last Update Posted Date | June 27, 2012 | ||
Study Start Date | January 2009 | ||
Actual Primary Completion Date | June 2011 (Final data collection date for primary outcome measure) | ||
Current Primary Outcome Measures |
to investigate onab/A- induced changes on gene expression of NGF, TRPV1, TrkA and p75 in bladder wall tissue of patients with neurogenic and idiopathic DO. All patients underwent cystoscopy with bladder wall biopsy specimens. After undergoing cystoscopy with bladder sampling patients underwent onab/A intradetrusorial injections. Patients were injected with 100 or 300 onab/A U according to the type of DO. Urodynamic studies and cystoscopies with bladder sampling were repeated 1 month later. NGF and neuroreceptors (TrkA, TRPV1, p75)gene expression have been measured with Real Time Polymerase Chain reaction. NGF bladder tissue content (protein) has been added into evaluation and measured with ELISA.
|
||
Original Primary Outcome Measures | Same as current | ||
Change History | No Changes Posted | ||
Current Secondary Outcome Measures |
|
||
Original Secondary Outcome Measures | Same as current | ||
Current Other Outcome Measures | Not Provided | ||
Original Other Outcome Measures | Not Provided | ||
Descriptive Information | |||
Brief Title | Onabotulinumtoxina Intradetrusorial Injections and NGF Expression | ||
Official Title | PHASE IV STUDY ON THE EFFECTS OF ONABOTULINUMTOXINA INTRADETRUSORIAL INJECTIONS ON BLADDER EXPRESSION OF NGF, TRKA, P75 AND TRPV1 IN PATIENTS WITH DETRUSOR OVERACTIVITY | ||
Brief Summary | In the last years, botulinum toxin type A (onab/A) has been increasingly used as a treatment option for overactive bladder symptoms in patients affected by either neurogenic and idiopathic detrusor overactivity (DO). How onab/A injected into the detrusor muscle improves overactive bladder symptoms in neurologic patients has been only partially investigated.Some evidence suggested that the neurotoxin probably reduces detrusor muscle contraction blocking detrusor muscle cholinergic innervation. However, recent experimental observations indicated that onab/A determines more complex effects on bladder activity acting on afferent innervations as well as on the efferent one. Only few experimental studies have investigated the activity of onab/A on bladder afferent nervous transmission. Experimental studies in animals showed that Nerve Growth Factor (NGF) elicits increased sensation, urgency and DO. Although there are some evidence on the ability of onab/A to improve DO and to reduce bladder and urinary content of NGF, how onab/A influences NGF expression and the expression of TrKa, p75 and TRPV1 receptors is still unclear. The hypothesis is that onab/A reduces NGF bladder tissue levels and in the same time it modulates the gene expression of NGF associated receptors (TrkA, p75 and TRPV1). | ||
Detailed Description | NGF has been suggested to modulate neurotransmitters' release, induces synaptic reorganization and influences neuronal excitability acting on Trk/A and p75 associated receptors. Moreover, recent observations indicated that NGF-induced DO and noxious input depend on the interaction of NGF with TRPV1, that is over-expressed in overactive bladders and interstitial cystitis/painful bladder syndrome. From a clinical point of view, a decrease in urinary NGF levels has been detected in patients with DO treated with onab/A. Although there are some evidence on the ability of onab/A to improve DO and to reduce bladder and urinary content of NGF, how onab/A influences NGF expression and the expression of TrKa, p75 and TRPV1 receptors is still unclear. | ||
Study Type | Observational | ||
Study Design | Observational Model: Cohort Time Perspective: Prospective |
||
Target Follow-Up Duration | Not Provided | ||
Biospecimen | Retention: Samples With DNA Description: Bladder biopsy specimens obtained from the postero-lateral wall of the bladder with cold cup resection. Deep bladder wall biopsy including urothelium and smooth muscle were performed. No biopsies were taken from the bladder neck or the trigone. |
||
Sampling Method | Non-Probability Sample | ||
Study Population | We consecutively enrolled 18 patients with neurogenic DO (8 patients with spinal cord injury: 7 men and 1 women, mean age: 46±2 yrs, disease duration 6.25±1 yrs; 10 patients with suprapontine bilateral lesions: 4 men and 6 women, mean age: 55±4 yrs, disease duration 6.6±1.49 yrs ) and 7 with idiopathic DO (3 men and 4 female, mean age: 53±5 yrs, disease duration 7.1±1.53 yrs). All the patients had overactive bladder (OAB) symptoms and DO refractory to conventional anticholinergics (at least 3 antimuscarinic agents -- tolterodine, oxybutynin and solifenacin -- each taken for at least 1 month). Anticholinergics were discontinued one month before entry into the study. | ||
Condition |
|
||
Intervention | Not Provided | ||
Study Groups/Cohorts | botulinum A toxin
18 patients with neurogenic DO and 7 with idiopathic DO All the patients had overactive bladder (OAB) symptoms and DO refractory to conventional anticholinergics. |
||
Publications * | Not Provided | ||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||
Recruitment Information | |||
Recruitment Status | Completed | ||
Actual Enrollment |
25 | ||
Original Actual Enrollment | Same as current | ||
Actual Study Completion Date | March 2012 | ||
Actual Primary Completion Date | June 2011 (Final data collection date for primary outcome measure) | ||
Eligibility Criteria | Inclusion Criteria: Patients affected by refractory overactive bladder (OAB) symptoms and detrusor overactivity (idiopathic and neurogenic DO) refractory to conventional anticholinergics (at least 3 antimuscarinic agents -- tolterodine, oxybutynin and solifenacin -- each taken for at least 1 month). Exclusion Criteria:
|
||
Sex/Gender |
|
||
Ages | 18 Years to 80 Years (Adult, Senior) | ||
Accepts Healthy Volunteers | No | ||
Contacts | Contact information is only displayed when the study is recruiting subjects | ||
Listed Location Countries | Italy | ||
Removed Location Countries | |||
Administrative Information | |||
NCT Number | NCT01629433 | ||
Other Study ID Numbers | onabotulinumatoxin and NGF | ||
Has Data Monitoring Committee | Yes | ||
U.S. FDA-regulated Product | Not Provided | ||
IPD Sharing Statement | Not Provided | ||
Responsible Party | Antonella Giannantoni, University Of Perugia | ||
Study Sponsor | University Of Perugia | ||
Collaborators | Allergan | ||
Investigators | Not Provided | ||
PRS Account | University Of Perugia | ||
Verification Date | June 2012 |